Navigation Links
EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
Date:7/22/2009

WELLESLEY HILLS, Mass., July 22 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that assets of EPIX Pharmaceuticals, Inc. ("EPIX") have been assigned to him for the benefit of EPIX's creditors.

EPIX's products and services focus on the discovery and development of novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. In addition, EPIX has several programs related to its MRI imaging business, including a commercial MRI imaging drug in Europe, (MS-325), formerly marketed as Vasorist(R), gadofosveset trisodium, by Bayer Schering Pharma.) EPIX also has collaborations with several leading pharmaceutical and research foundations.

The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction, the time and date of which will be announced within a week.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or

jffinnjr@earthlink.net


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biostar Pharmaceuticals, Inc. Receives Government Approvals for Three New Products
2. Solvay Pharmaceuticals, Inc. Announces Commercial Availability of CREON(R) (Pancrelipase) Delayed-Release Capsules
3. Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan
4. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
5. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
6. Atlantic Pharmaceuticals, Inc. Announces Completion of Successful Pre-IND Meeting with FDA for Abuse Deterrent Narcotic
7. Lotus Pharmaceuticals, Inc. to Exhibit at the 2009 International Conference for Bioeconomy
8. Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
10. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
11. Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... Immunotherapy has emerged as one of the most promising options for the ... next revolution in our fight against this complex disease. One of the most effective ... such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry tests ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Neurim Pharmaceuticals ("Neurim") and ... exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... sleep disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic ... for children. The collaboration with Exeltis will help increase ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The global patient safety and risk management software ... geography. Patient safety has become a priority for ... developed significantly in the last decade and is currently on the ...
(Date:3/28/2017)... Md. , March 28, 2017 ... Dupixent (dupilumab) injection to treat adults with moderate-to-severe ... whose eczema is not controlled adequately by topical ... not advisable. Dupixent can be used with or ... Dupixent demonstrates our commitment to approving new and ...
Breaking Medicine Technology: